---
layout: default
title: Palivizumab
parent: 僅模型預測 (L5)
nav_order: 281
evidence_level: L5
indication_count: 10
---

# Palivizumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Palivizumab: From RSV Prophylaxis to Benign Neoplasm of Tongue

## One-Sentence Summary

Palivizumab is a humanized monoclonal antibody used to prevent respiratory syncytial virus (RSV) infection in high-risk infants. The TxGNN model predicts it may be effective for **benign neoplasm of tongue**, but this prediction is currently supported by **0 clinical trials** and **0 publications**.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | RSV (Respiratory Syncytial Virus) infection prophylaxis (based on known drug classification; not marketed in Finland, so no structured license text is available) |
| Predicted New Indication | Benign neoplasm of tongue |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 |
| Finland Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Palivizumab is a humanized monoclonal antibody that targets the RSV fusion (F) protein. It works by neutralizing the virus and blocking cell-to-cell fusion, making it a respiratory antiviral prophylactic agent rather than an oncology drug.

There is no known mechanistic link between neutralizing an RSV surface glycoprotein and the biology of a benign oral/tongue neoplasm. No shared pathway, receptor, or cellular process connects the two.

Notably, all top-10 TxGNN predictions for this drug (tongue neoplasm, epiglottis neoplasm, cervical neuroblastoma, hypopharynx neoplasm, floor-of-mouth neoplasm, testicular tumor, cystic neoplasm, jugular foramen schwannoma, mesenchymoma, thyroglossal duct cyst) cluster within a narrow score band (99.93–99.94%) and span unrelated head/neck and reproductive-organ pathologies. This pattern is more consistent with a structural artifact of the knowledge graph — e.g., node proximity within a pediatric/rare-disease ontology cluster — than with a genuine causal signal. No clinical or literature evidence currently supports any of these ten predictions.

## Clinical Trial Evidence

Currently no related clinical trials registered

## Literature Evidence

Currently no related literature available

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction has a high TxGNN score but zero supporting clinical trials or literature, and the drug's known mechanism (RSV F-protein neutralization) has no plausible biological connection to tongue neoplasia. The clustering of ten unrelated neoplasm predictions at nearly identical scores further suggests a graph-embedding artifact rather than a real signal (Evidence Level L5, Decision Stage S0).

**To proceed, the following is needed:**
- TFDA/regulatory package insert data (currently a Blocking data gap, DG001)
- Confirmed mechanism of action from DrugBank or primary literature (High-priority data gap, DG002)
- Independent preclinical or biological plausibility review before any further evidence search is justified
- Re-evaluation of TxGNN output for signs of ontology-cluster bias across the full head/neck-neoplasm prediction set
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

